Inclusion Criteria:  Patients who were diagnosed as metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma by histopathology or cytology, at least one measurable lesion conforming to RECIST 1.1 criteria. Disease progresses or intolerance for first-line standard treatment, including patients who relapsed or metastasized within 6 months of neoadjuvant or adjuvant therapy ECOG score 0-2 Adequate organ and bone marrow function The expected survival time is ≥ 12 weeks Had normal swallowing function, without dysfunction of gastrointestinal absorption Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures  Exclusion Criteria:  The patient has previously received anti-angiogenic drugs or albumin-bound paclitaxel; The first study drug treatment was less than 2 weeks or 5 half-lives (in terms of longer) from the last chemotherapy or 5 half-lives from the last targeted therapy Known to be allergic to the active ingredients or excipients in this study. Had other active malignant tumors within 5 years before entering the study. Subject with cerebral metastasis Have a clear history of serious and uncontrolled other disease or mental disorders; Other chemotherapy, targeted therapy, hormonotherapy, immunotherapy, radiotherapy or traditional Chinese medicine should be used for anti-tumor therapy Other situations that the researcher considers inappropriate to participate in the research.